Drug provision and health technology assessment in France
https://doi.org/10.17749/2070-4909.2020.13.1.71-83
Abstract
About the Authors
V. V. OmelyanovskiyRussian Federation
Vitaly V. Omelyanovskiy – MD, Dr Sci Med, Professor, General Director ; Head of the Center for Healthcare Funding
Researcher ID: P-6911-2018; Scopus Author ID: 6507287753
A. V. Nikitina
Russian Federation
Anna V. Nikitina – Chief Specialist at the Department of Methodological Support of Comprehensive Health Technology Assessment
V. A. Lemeshko
Russian Federation
Valeriya A. Lemeshko – Deputy Head of the Department of Methodological Support of Comprehensive Health Technology Assessment; Research assistant at the Center for Healthcare Funding; Post-graduate student at the Department of Pharmacology
G. R. Khachatryan
Russian Federation
Georgii R. Khachatryan – Head of the Department of Methodological Support of Comprehensive Health Technology Assessment; Junior Researcher at the Center for Healthcare Funding
References
1. T’erri G., Ani O. Comparative analysis of health care reforms in France and Russia. Vestnik Rossiiskogo universiteta druzhby narodov. Seriya: Ekonomika. 2014; №. 3. (in Russ.).
2. Health system in France [Electronic resource]. URL: https://ru.ambafrance.org/IMG/pdf/systeme_de_sante_ru_1_.pdf?24120/7e3f5299ceef57e00db948fd814b92b0701efa16. Accessed: 12.03.2020.
3. International Profiles of Health Care Systems, 2012 [Electronic resource]. URL: http://apps.who.int/medicinedocs/documents/s19988en/s19988en.pdf. Accessed: 12.03.2020.
4. The French Social Security System. [Electronic resource]. URL: http://www.cleiss.fr/docs/regimes/regime_france/an_1.html. Accessed: 12.03.2020.
5. Healthcare expenditure statistics. Eurostat. [Electronic resource]. URL: https://ec.europa.eu/eurostat/statistics-explained/index. php/Healthcare_expenditure_statistics#Healthcare_expenditure_by_ financing_scheme. Accessed: 12.03.2020.
6. The French Health Care System. [Electronic resource]. URL: http://international.commonwealthfund.org/countries/france. Accessed: 10.03.2020.
7. Health system: time for change. [Electronic resource]. URL: http://www.euro.who.int/__data/assets/pdf_file/0003/155550/ E94856sumR.pdf. Accessed: 12.03.2020.
8. Solodkii V.A., Perkhov V.I., Stebunova R.V. Review of France’s health care reform over the past twenty years. Menedzher zdravookhraneniya. 2012; 1: 36-48. (in Russ.).
9. Chevreul K., Brigham B., Durand-Zaleski I., et al. France: health system review 2015. Health systems in transition. 2015;17(3):1-218.
10. Garrido M., Kristensen F., Busse R., et al. Health technology assessment and health policy-making in Europe: current status, challenges and potential. WHO Regional Office Europe. 2008; 14: 1-197.
11. National Authority for Health: France.2009, [Electronic resource] URL: https://pdfs.semanticscholar.org/92b7/27ce2c33e71434d9d6c16281fc2b3f0107ab.pdf. Accessed: 12.03.2020.
12. Haute Autoritе` de Santе` [Electronic resource] URL: https:// www.has-sante.fr/portail/. Accessed: 12.03.2020.
13. Lopes S., Marty Ch., Berdai B.: PHIS Pharma Profile France 2011. Pharmaceutical Health Information System; Commissioned by the European Commission, Executive Agency for Health and Consumers and the Austrian Federal Ministry of Health, 2011. [Electronic resource] URL: https://ppri.goeg.at/sites/ppri.goeg.at/files/inline-files/PHIS_Pharma%20Profile%20FR_2011_final_1.pdf. Accessed: 12.03.2020.
14. Doctrine de la commission de la transparence. Principes d’е`valuation de la CT relatifs aux mе`dicaments en vue de leur accе`s au remboursement. [Electronic resource] URL: https://www.has-sante.fr/upload/docs/application/pdf/2018-10/doctrine_10102018.pdf. Accessed: 12.03.2020.
15. General method for assessing health technologies [Electronic resource]. URL: https://www.has-sante.fr/portail/upload/docs/application/pdf/general_method_eval_techno.pdf. Accessed: 10.03.2020.
16. Les modalitе`s actuelles de remboursement des anticancе`reux – Quelles е`volutions possibles ? [Electronic resource]. URL: https://oncocdn.keeo.com/les-modalites-actuelles-de-remboursement-antic-22202.pdf. Accessed: 10.03.2020.
17. Rе`muzat C., Toumi M., Falissard B. New drug regulations in France: what are the impacts on market access? Part 1–overview of new drug regulations in France. Journal of Market Access & Health Policy. 2013; 1 (1): 20891.
18. Toumi M., Motrunich A., Millier A., et al. Analysis of health economics assessment reports for pharmaceuticals in France–understanding the underlying philosophy of CEESP assessment. Journal of market access & health policy. 2017; 5 (1): 1344088.
19. Toumi M., Rе`muzat S., Hammi E., et al. Current process and future path for health economic assessment of pharmaceuticals in France. Journal of market access & health policy. 2015; 3 (1): 27902.
20. Zorginstituut Nederland [Electronic resource]. URL: https:// www.zorginstituutnederland.nl/. Accessed: 10.03.2020.
21. Introduction to HTA. Educational Seminar ISPOR Dubai – September 19, 2018 [Electronic resource]. URL: https://www.ispor.org/ docs/default-source/default-document-library/3-sept-19_educational-seminar-introduction-to-hta8ec28fed4b0246089d84e40684dcf2d9. pdf?sfvrsn=62f34682_0. Accessed: 10.03.2020.
22. Akehurst R.L., Abadie E., Renaudin N., et al. Variation in health technology assessment and reimbursement processes in Europe. Value in Health. 2017; 20 (1): 67-76.
23. Horscroft J.A., Chapman A., Philips Z., et al. Variation In Health Technology Assessment And Reimbursement Decisions In England, France, And Germany: Spotlight On The Impact Of Uncertainty. Value in Health. 2017; 20 (9): A468-A468.
24. Choices in Methods for Economic Evaluation [Electronic resource]. URL: https://www.has-sante.fr/portail/upload/docs/application/pdf/2012-10/choices_in_methods_for_economic_evaluation.pdf. Accessed:10.03.2020.
25. Vlachaki I., Ovcinnikova O., Storck C., et al. Comparison of Early Scientific Advice Processes in UK, France and Germany (HTA Only): Tips and Tricks. Value in Health, Vol. 20, No. 9 (October 2017) [Electronic resource]. URL: https://www.ispor.org/docs/default-source/ispor-20th-annual-european-congress/php267--strong-u-vlachaki-i-u-sup-1-sup-strong-ovcinnikova-o-sup-1-sup-storck-c-sup-2-sup-el-mouaddin-n-sup-3-sup-shah-msup-4-sup-br-sup-1-sup-mapi-london-uk-sup-2-sup-mapi-munich-germany-sup-3-sup-m.pdf?sfvrsn=97410100_0. Accessed: 12.03.2020.
Review
For citations:
Omelyanovskiy V.V., Nikitina A.V., Lemeshko V.A., Khachatryan G.R. Drug provision and health technology assessment in France. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020;13(1):71-83. (In Russ.) https://doi.org/10.17749/2070-4909.2020.13.1.71-83
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.